Swiss National Bank Has $19.49 Million Stock Position in DaVita Inc. (NYSE:DVA)

Swiss National Bank decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 16.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 130,300 shares of the company's stock after selling 25,900 shares during the period. Swiss National Bank owned 0.16% of DaVita worth $19,486,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new position in DaVita during the fourth quarter valued at about $41,000. Quarry LP bought a new position in DaVita during the third quarter valued at about $60,000. Venturi Wealth Management LLC raised its holdings in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after buying an additional 152 shares in the last quarter. Versant Capital Management Inc raised its holdings in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after buying an additional 169 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after buying an additional 131 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

DaVita Stock Performance

Shares of DaVita stock traded down $0.76 during trading on Friday, reaching $148.25. The company's stock had a trading volume of 1,036,193 shares, compared to its average volume of 783,456. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market cap of $11.86 billion, a price-to-earnings ratio of 13.80, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The business's fifty day moving average price is $158.53 and its 200-day moving average price is $157.48.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, equities research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DVA shares. StockNews.com lowered DaVita from a "buy" rating to a "hold" rating in a report on Friday. Barclays raised their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, DaVita has a consensus rating of "Hold" and an average price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.